
Systemic Biological Therapies for Psoriasis





Choice of Biologic then dependent upon:-

- Cost effectiveness, dosing schedule as per patient needs and patient device/route preference (Adalimumab or Etanercept biosimilar first line when clinically appropriate)
- Proven efficacy and safety profile in long term use
- Patient co-morbidities
- Ease vs complexity of monitoring
- Ustekinumab dose escalation for patients <100 Kg based on patient's response to treatment, local, regional and national experience and close monitoring of effectiveness and side effects profile

References: Specialist Pharmacy Service. Updated RMOC Advisory Statement: Sequential Use of Biologics. [Internet]. 2020. [Cited March 2022]. Available from https://www.sps.nhs.uk/articles/rmoc-advisory-statement-sequential-use-of-biologic-medicines/